What is Haemonetics Corp Mass's earnings per share (EPS)?

Haemonetics Corp Mass (HAE) reported diluted earnings per share of $2.05 for fiscal year 2026. This represents a -38.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Haemonetics Corp Mass (HAE) Financials

HAE

Trailing 12 months to June 27, 2026

Revenue $1.4B +0.4% YoY

Net Income -$924K +77.9% YoY

EPS (Diluted) $2.07 -36.7% YoY

Free Cash Flow $291.2M +53.9% YoY

Market Cap $4.6B as of Sep 10, 2026

Price / Sales 3.4x on $1.4B revenue, trailing 12 months to June 27, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 27, 2026

Price / Book 5.5x on $837.1M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 27, 2026 Reported Aug 6, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HAE SEC filings page.

Haemonetics Corp Mass (HAE) reported $1.4B in revenue over the twelve months to Jun 27, 2026, up 0.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HAE FY2026 2026-08-30

Haemonetics’ dominant mechanic is cash generation strengthening despite operating-profit pressure, alongside more leveraged capital allocation.

In FY2026, operating cash flow reached $293M and free cash flow reached $260M, revealing cash output that operating income alone does not explain. That improvement came as operating margin fell from 16.3% in FY2025 to 11.8%, so reported cash performance was not simply the result of stronger operating profitability.

Gross margin expansion from 55.0% to 59.0% while revenue contracted points to cost or mix effects rather than a volume-led improvement. Yet operating margin compressed to 11.8%, showing that expenses below gross profit absorbed much of the gain.

The current ratio rose from 1.6x to 3.0x, but that short-term improvement coincided with a shift toward longer-term financing rather than broad deleveraging. Long-term debt increased while equity declined; debt-to-equity reached 1.5x after share buybacks totaled $175M, so capital returns amplified leverage.

Financial Health Signals

Financial Health Score 58/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Haemonetics Corp Mass's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Haemonetics Corp Mass has an operating margin of 11.8%, meaning the company retains $12 of operating profit per $100 of revenue. This strong profitability earns a score of 74/100, reflecting efficient cost management and pricing power. This is down from 16.3% the prior year.

Growth

Haemonetics Corp Mass's revenue declined 2.0% year-over-year, from $1.4B to $1.3B. This contraction results in a growth score of 34/100.

Leverage

Haemonetics Corp Mass has elevated debt relative to equity (D/E of 1.53), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 17/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.95, Haemonetics Corp Mass holds $2.95 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

Haemonetics Corp Mass converts 19.5% of revenue into free cash flow ($260.4M). This strong cash generation earns a score of 78/100.

Returns

Haemonetics Corp Mass earns a strong 0.0% return on equity (ROE), meaning it generates less than $1 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 67/100. This is unchanged from the prior year.

Altman Z-Score Grey Zone

2.94

Haemonetics Corp Mass scores 2.94, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($4.6B) relative to total liabilities ($1.6B). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Haemonetics Corp Mass passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

N/A

Haemonetics Corp Mass reported $97K of net income while generating $293.2M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.

Interest Coverage Safe

8.12x

Haemonetics Corp Mass earns $8.12 in operating income for every $1 of interest expense ($156.7M vs $19.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$339.4M

YoY+5.6%

QoQ-2.0%

5Y CAGR+7.1%

10Y CAGR+4.7%

Haemonetics Corp Mass generated $339.4M in revenue in Q1 2027. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is down 2.0%.

EBITDA

$84.6M

YoY+2.3%

QoQ+1869.5%

5Y CAGR+6.7%

10Y CAGR+12.6%

Haemonetics Corp Mass's EBITDA was $84.6M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.3% from the same quarter a year earlier. Against the prior quarter it is up 1869.5%.

Net Income

$33.0M

YoY-3.0%

QoQ+128.1%

5Y CAGR+0.7%

Haemonetics Corp Mass reported $33.0M in net income in Q1 2027. This represents a decrease of 3.0% from the same quarter a year earlier. Against the prior quarter it is up 128.1%.

EPS (Diluted)

$0.72

YoY+2.9%

5Y CAGR+3.0%

Haemonetics Corp Mass earned $0.72 per diluted share (EPS) in Q1 2027. This represents an increase of 2.9% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

$44.4M

YoY+225.6%

QoQ-16.6%

5Y CAGR-4.8%

Haemonetics Corp Mass generated $44.4M in free cash flow in Q1 2027, representing cash available after capex. This represents an increase of 225.6% from the same quarter a year earlier. Against the prior quarter it is down 16.6%.

Cash & Debt

$223.4M

YoY-23.7%

QoQ-9.0%

5Y CAGR+3.4%

10Y CAGR+7.1%

Haemonetics Corp Mass held $223.4M in cash against $1.2B in long-term debt as of Q1 2027.

Shares Outstanding

45M

YoY-5.6%

5Y CAGR-2.2%

10Y CAGR-1.1%

Haemonetics Corp Mass had 45M shares outstanding in Q1 2027. This represents a decrease of 5.6% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

59.8%

YoY-0.1pp

QoQ+2.5pp

5Y CAGR+9.7pp

10Y CAGR+11.7pp

Haemonetics Corp Mass's gross margin was 59.8% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.

Operating Margin

16.9%

YoY+0.2pp

QoQ+23.6pp

5Y CAGR+0.1pp

10Y CAGR+15.2pp

Haemonetics Corp Mass's operating margin was 16.9% in Q1 2027, reflecting core business profitability. This is up 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 23.6 percentage points.

Net Margin

9.7%

YoY-0.9pp

QoQ+43.6pp

5Y CAGR-3.5pp

10Y CAGR+9.9pp

Haemonetics Corp Mass's net profit margin was 9.7% in Q1 2027, showing the share of revenue converted to profit. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 43.6 percentage points.

Return on Equity

3.9%

YoY+0.1pp

QoQ+18.7pp

5Y CAGR-0.5pp

10Y CAGR+4.0pp

Haemonetics Corp Mass's ROE was 3.9% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 18.7 percentage points.

Capital Allocation

R&D Spending

$16.2M

YoY-0.4%

QoQ+12.1%

Haemonetics Corp Mass invested $16.2M in research and development in Q1 2027. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is up 12.1%.

Capital Expenditures

$7.9M

YoY+110.6%

QoQ-55.2%

5Y CAGR-3.3%

10Y CAGR-10.6%

Haemonetics Corp Mass invested $7.9M in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 110.6% from the same quarter a year earlier. Against the prior quarter it is down 55.2%.

Share Buybacks

Not reported for Q1 2027.

HAE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HAE quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$1.4B	$1.3B-2.0%	$1.4B+4.0%	$1.3B+12.0%	$1.2B+17.7%	$993.2M+14.1%	$870.5M-11.9%	$988.5M+2.2%	$967.6M+7.0%	$903.9M+2.0%	$886.1M-2.5%	$908.8M-0.2%	$910.4M-3.0%	$938.5M+5.2%	$892.0M+22.6%	$727.8M
Cost of Revenue	$553.9M	$546.4M-10.7%	$611.9M-0.9%	$617.5M+11.6%	$553.6M+13.5%	$487.7M+3.2%	$472.6M-6.2%	$504.0M-8.4%	$550.0M+11.8%	$492.0M-3.1%	$507.6M+0.9%	$502.9M+5.7%	$476.0M+1.2%	$470.1M+1.4%	$463.9M+29.4%	$358.6M
Gross Profit	$798.1M	$787.6M+5.2%	$749.0M+8.3%	$691.5M+12.4%	$615.1M+21.7%	$505.5M+27.1%	$397.8M-17.9%	$484.5M+16.0%	$417.5M+1.4%	$411.9M+8.8%	$378.5M-6.8%	$405.9M-6.6%	$434.4M-7.2%	$468.4M+9.4%	$428.1M+15.9%	$369.2M
R&D Expenses	$59.7M	$59.8M-4.7%	$62.7M+15.2%	$54.4M+8.6%	$50.1M+7.1%	$46.8M+42.4%	$32.9M+6.4%	$30.9M-13.5%	$35.7M-9.0%	$39.2M+4.5%	$37.6M-16.5%	$45.0M-17.0%	$54.2M0.0%	$54.2M+22.1%	$44.4M+20.6%	$36.8M
SG&A Expenses	$450.6M	$442.4M+1.3%	$436.8M+1.6%	$429.8M+14.1%	$376.7M+10.7%	$340.1M+23.6%	$275.2M-2.4%	$282.0M+3.1%	$273.5M-13.6%	$316.5M+4.9%	$301.7M-4.9%	$317.2M-5.9%	$337.2M-7.9%	$366.0M+13.3%	$323.1M+32.6%	$243.7M
Operating Income	$160.3M	$156.7M-29.3%	$221.8M+34.5%	$164.9M+5.7%	$156.0M+93.2%	$80.8M-10.0%	$89.7M-13.2%	$103.4M+23.7%	$83.5M+48.8%	$56.2M+389.8%	-$19.4M+55.9%	-$43.9M-208.4%	$40.5M-12.7%	$46.4M-17.7%	$56.4M-36.4%	$88.8M
EBITDA	N/A	$268.5M-20.4%	$337.4M+28.7%	$262.1M+5.1%	$249.3M+39.7%	$178.5M+2.6%	$174.0M-18.5%	$213.6M+10.7%	$193.0M+32.7%	$145.4M+106.7%	$70.4M+53.0%	$46.0M-63.7%	$126.6M-1.2%	$128.2M+5.1%	$121.9M-12.1%	$138.7M
Interest Expense	N/A	$19.3M-46.2%	$35.9M+84.1%	$19.5M+50.0%	$13.0M+124.1%	$5.8M-38.3%	$9.4M-30.4%	$13.5M+7.1%	$12.6M+63.6%	$7.7M	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$34.1M	$30.7M-30.8%	$44.4M+29.4%	$34.3M+31.9%	$26.0M+28.4%	$20.3M+408.9%	-$6.6M-161.7%	$10.6M-42.9%	$18.6M+32.4%	$14.1M+1263.9%	-$1.2M-155.8%	$2.2M-84.8%	$14.3M+1038.7%	$1.3M-88.7%	$11.1M-50.9%	$22.6M
Net Income	-$924K	$97K-42.0%	$168K-99.9%	$117.6M+1.9%	$115.4M+166.1%	$43.4M-45.4%	$79.5M+3.8%	$76.5M+39.1%	$55.0M+20.7%	$45.6M+273.5%	-$26.3M+52.7%	-$55.6M-428.9%	$16.9M-51.9%	$35.1M-9.4%	$38.8M-42.0%	$66.9M
EPS (Basic)	N/A	$2.06-38.1%	$3.33+43.5%	$2.32+2.2%	$2.27+167.1%	$0.85-45.9%	$1.57+4.0%	$1.51+41.1%	$1.07+24.4%	$0.86+268.6%	-$0.51+53.2%	-$1.09-430.3%	$0.33-51.5%	$0.68-10.5%	$0.76-42.4%	$1.32
EPS (Diluted)	$2.07	$2.05-38.1%	$3.31	$2.29+2.2%	$2.24+166.7%	$0.84-45.8%	$1.55+4.7%	$1.48+42.3%	$1.04+22.4%	$0.85+266.7%	-$0.51+53.2%	-$1.09-440.6%	$0.32-52.2%	$0.67-9.5%	$0.74	$1.30
Diluted Shares (Avg)	N/A	47M-6.7%	51M	51M0.0%	51M+0.1%	51M+0.1%	51M-1.0%	52M-2.1%	53M-1.0%	54M+3.8%	52M+1.2%	51M-2.3%	52M-0.5%	52M+0.2%	52M	52M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$339.4M+5.6%	$346.4M+4.8%	$339.0M-2.7%	$327.3M-5.3%	$321.4M-4.4%	$330.6M-3.7%	$348.5M+3.7%	$345.5M+8.6%
Cost of Revenue	$136.6M+5.8%	$148.1M+7.7%	$136.6M-11.9%	$132.6M-16.1%	$129.2M-19.9%	$137.5M-17.8%	$155.0M-2.1%	$158.1M+7.0%
Gross Profit	$202.8M+5.5%	$198.2M+2.7%	$202.4M+4.6%	$194.7M+3.9%	$192.2M+9.9%	$193.1M+9.7%	$193.5M+8.8%	$187.4M+9.9%
R&D Expenses	$16.2M-0.4%	$14.4M-21.1%	$14.2M-10.4%	$14.9M+5.2%	$16.3M+12.5%	$18.3M+15.4%	$15.8M+19.3%	$14.1M+11.6%
SG&A Expenses	$118.9M+7.4%	$120.9M+5.0%	$109.2M+2.5%	$101.6M-5.0%	$110.7M+2.3%	$115.1M+5.4%	$106.5M-4.7%	$106.9M-7.3%
Operating Income	$57.5M+6.7%	-$23.0M-132.3%	$67.4M+14.2%	$58.5M+13.1%	$53.9M+35.5%	$71.3M+138.2%	$59.0M+28.4%	$51.7M+46.4%
EBITDA	$84.6M+2.3%	$4.3M-95.7%	$94.8M+7.6%	$86.7M+7.2%	$82.6M+19.9%	$99.5M+72.7%	$88.1M+26.7%	$80.9M+38.8%
Income Tax	$14.6M+30.8%	-$8.3M-164.7%	$15.2M+22.6%	$12.6M+15.9%	$11.1M+33.5%	$12.8M+318.6%	$12.4M-2.9%	$10.9M+37.2%
Net Income	$33.0M-3.0%	-$117.4M-7.1%	$44.7M+19.3%	$38.7M+14.3%	$34.0M-11.3%	-$109.5M-637.8%	$37.5M+20.0%	$33.8M+35.8%
EPS (Basic)	$0.73+2.8%	-$0.41-135.0%	$0.96+28.0%	$0.81+22.7%	$0.71-5.3%	$1.17+192.5%	$0.75+21.0%	$0.66+34.7%
EPS (Diluted)	$0.72+2.9%	-$0.41-135.0%	$0.95+28.4%	$0.81+22.7%	$0.70-5.4%	$1.17+192.5%	$0.74+21.3%	$0.66+37.5%
Diluted Shares (Avg)	46M-5.5%	N/A	47M-7.2%	48M-7.0%	48M-6.2%	N/A	51M-1.6%	51M-0.3%

Not reported in any period shown, so not listed: Interest Expense.

HAE Balance Sheet

HAE quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$2.4B-2.2%	$2.5B+11.6%	$2.2B+13.5%	$1.9B+4.0%	$1.9B+2.2%	$1.8B+43.6%	$1.3B-0.6%	$1.3B+3.0%	$1.2B-0.1%	$1.2B-6.1%	$1.3B-11.2%	$1.5B-1.9%	$1.5B+3.6%	$1.5B+60.5%	$911.1M
Current Assets	$834.9M-10.7%	$935.0M+21.6%	$768.9M-0.1%	$769.7M+1.8%	$756.0M+9.0%	$693.5M+14.9%	$603.6M+4.8%	$576.1M+10.5%	$521.2M+2.2%	$510.0M+4.5%	$488.1M-12.5%	$557.7M-10.5%	$623.0M+4.3%	$597.0M+13.3%	$527.1M
Cash & Equivalents	$245.4M-20.0%	$306.8M+71.6%	$178.8M-37.1%	$284.5M+9.6%	$259.5M+34.9%	$192.3M+40.1%	$137.3M-18.9%	$169.4M-6.0%	$180.2M+29.1%	$139.6M+21.2%	$115.1M-28.3%	$160.7M-16.5%	$192.5M+7.5%	$179.1M-21.7%	$228.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$306.4M-16.1%	$365.1M+15.1%	$317.2M+22.3%	$259.4M-11.5%	$293.0M-9.2%	$322.6M+19.4%	$270.3M+39.1%	$194.3M+20.9%	$160.8M-9.1%	$176.9M-5.4%	$187.0M-11.4%	$211.1M+6.8%	$197.7M+7.6%	$183.8M+56.9%	$117.2M
Accounts Receivable	$216.9M+7.0%	$202.7M-1.9%	$206.6M+15.3%	$179.1M+12.4%	$159.4M+24.9%	$127.6M-22.8%	$165.2M-10.7%	$185.0M+22.4%	$151.2M-1.0%	$152.7M-2.8%	$157.1M+7.7%	$145.8M-11.4%	$164.6M-3.2%	$170.1M+25.6%	$135.5M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$656.4M+8.6%	$604.3M+6.9%	$565.1M+21.2%	$466.2M-0.2%	$467.3M+0.2%	$466.4M+121.4%	$210.7M-0.1%	$210.8M-0.3%	$211.4M+0.3%	$210.8M-21.3%	$267.8M-19.9%	$334.3M-0.7%	$336.8M+1.9%	$330.5M+187.2%	$115.1M
Total Liabilities	$1.6B-1.9%	$1.6B+31.9%	$1.2B+10.6%	$1.1B+0.6%	$1.1B+2.0%	$1.1B+60.0%	$680.0M+12.0%	$606.9M+25.2%	$484.9M-2.8%	$499.1M-16.5%	$597.6M-9.4%	$659.3M-2.5%	$676.3M-2.4%	$692.7M+288.1%	$178.5M
Current Liabilities	$282.6M-51.1%	$578.1M+92.5%	$300.4M+19.3%	$251.8M-43.1%	$442.3M+74.5%	$253.5M-7.8%	$274.8M+16.6%	$235.8M-38.7%	$384.7M+82.2%	$211.2M+13.8%	$185.6M-1.7%	$188.7M-13.0%	$216.9M+20.4%	$180.1M+37.8%	$130.7M
Non-Current Liabilities	$1.3B+25.2%	$1.1B+12.5%	$935.2M+8.1%	$865.0M+29.5%	$668.0M-20.0%	$834.8M+106.0%	$405.2M+9.2%	$371.1M+270.4%	$100.2M-65.2%	$287.9M-30.1%	$412.0M-12.5%	$470.6M+2.4%	$459.4M-10.4%	$512.6M+973.3%	$47.8M
Long-Term Debt	$1.2B+32.4%	$921.2M+15.5%	$797.6M+5.8%	$754.1M+34.8%	$559.4M-19.0%	$690.6M+126.0%	$305.5M-5.3%	$322.5M+442.6%	$59.4M-76.6%	$253.6M-30.4%	$364.5M-10.3%	$406.4M+3.7%	$392.1M-14.2%	$456.9M+15782.7%	$2.9M
Total Equity	$796.3M-3.0%	$820.8M-14.5%	$960.0M+17.4%	$818.0M+9.2%	$749.4M+2.4%	$731.7M+24.6%	$587.1M-12.1%	$667.9M-11.2%	$752.4M+1.7%	$739.6M+2.5%	$721.6M-12.7%	$826.1M-1.4%	$837.9M+8.9%	$769.2M+5.0%	$732.6M
Retained Earnings	$279.3M-20.7%	$352.2M-2.3%	$360.5M+42.4%	$253.2M+25.1%	$202.4M+28.1%	$158.0M+101.2%	$78.5M-51.4%	$161.4M-39.5%	$266.9M-7.9%	$289.9M-8.3%	$316.2M-24.8%	$420.4M-3.0%	$433.3M+8.8%	$398.2M-0.6%	$400.8M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$2.4B-3.9%	$2.4B-2.2%	$2.5B-1.6%	$2.4B-3.3%	$2.5B-3.1%	$2.5B+11.6%	$2.5B+15.0%	$2.5B+25.6%
Current Assets	$810.8M-11.2%	$834.9M-10.7%	$943.7M-6.2%	$899.7M-5.9%	$913.2M-6.7%	$935.0M+21.6%	$1.0B+31.5%	$955.9M+10.4%
Cash & Equivalents	$223.4M-23.7%	$245.4M-20.0%	$363.4M+13.3%	$296.4M-1.0%	$292.9M-15.0%	$306.8M+71.6%	$320.8M+65.4%	$299.3M-14.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$306.7M-14.9%	$306.4M-16.1%	$321.2M-10.7%	$336.2M-12.0%	$360.5M-3.5%	$365.1M+15.1%	$359.6M+18.3%	$382.1M+33.7%
Accounts Receivable	$216.1M+7.6%	$216.9M+7.0%	$195.7M-7.7%	$207.1M-3.0%	$200.8M-0.4%	$202.7M-1.9%	$211.9M+0.2%	$213.5M+22.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$656.9M+8.2%	$656.4M+8.6%	$606.8M+0.3%	$606.1M-1.6%	$607.3M-1.0%	$604.3M+6.9%	$605.3M+9.1%	$616.2M+32.4%
Total Liabilities	$1.5B-3.3%	$1.6B-1.9%	$1.6B-2.8%	$1.6B-3.2%	$1.6B-3.4%	$1.6B+31.9%	$1.6B+29.2%	$1.6B+47.3%
Current Liabilities	$263.2M-50.5%	$282.6M-51.1%	$539.9M+113.2%	$548.3M+100.2%	$531.4M+104.3%	$578.1M+92.5%	$253.2M-3.3%	$273.9M+3.7%
Non-Current Liabilities	$1.3B+20.7%	$1.3B+25.2%	$1.0B-24.2%	$1.0B-23.9%	$1.0B-23.8%	$1.1B+12.5%	$1.4B+37.8%	$1.4B+60.8%
Long-Term Debt	$1.2B+27.0%	$1.2B+32.4%	$920.0M-24.6%	$920.4M-24.5%	$920.8M-24.4%	$921.2M+15.5%	$1.2B+42.4%	$1.2B+62.9%
Total Equity	$837.1M-5.1%	$796.3M-3.0%	$911.5M+0.5%	$849.2M-3.4%	$882.3M-2.5%	$820.8M-14.5%	$906.9M-3.9%	$878.9M-1.7%
Retained Earnings	$311.5M-12.5%	$279.3M-20.7%	$381.1M-2.8%	$336.3M-8.7%	$356.0M-7.9%	$352.2M-2.3%	$392.2M+15.3%	$368.5M+19.3%

HAE Cash Flow Statement

HAE quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$328.1M	$293.2M+61.4%	$181.7M0.0%	$181.8M-33.4%	$273.1M+58.5%	$172.3M+58.3%	$108.8M-31.2%	$158.2M-0.7%	$159.3M-27.7%	$220.3M+37.9%	$159.7M+31.1%	$121.9M-4.2%	$127.2M-8.8%	$139.5M+64.0%	$85.1M-26.2%	$115.3M
Depreciation & Amortization	N/A	$111.7M-3.3%	$115.6M+18.9%	$97.2M+4.2%	$93.3M-4.5%	$97.7M+16.0%	$84.3M-23.6%	$110.3M+0.8%	$109.4M+22.6%	$89.2M-0.5%	$89.7M-0.2%	$89.9M+4.5%	$86.1M+5.3%	$81.7M+24.8%	$65.5M+31.1%	$50.0M
Stock-Based Compensation	N/A	$33.8M+14.1%	$29.6M+4.6%	$28.3M+10.7%	$25.6M+5.0%	$24.4M-4.5%	$25.5M+24.7%	$20.5M+19.0%	$17.2M+32.0%	$13.0M+42.3%	$9.2M+31.7%	$6.9M-50.7%	$14.1M+7.7%	$13.1M+19.3%	$11.0M+18.1%	$9.3M
Capital Expenditures	$36.9M	$32.8M-16.5%	$39.3M+3.0%	$38.1M-80.1%	$191.3M+98.2%	$96.5M+160.6%	$37.0M-24.0%	$48.8M-59.0%	$119.0M+59.0%	$74.8M-1.8%	$76.1M-25.7%	$102.4M-16.2%	$122.2M+66.0%	$73.6M+18.4%	$62.2M+16.9%	$53.2M
Free Cash Flow	$291.2M	$260.4M+82.8%	$142.4M-0.8%	$143.6M+75.7%	$81.7M+7.9%	$75.8M+5.6%	$71.8M-34.4%	$109.5M+171.5%	$40.3M-72.3%	$145.6M+74.1%	$83.6M+329.6%	$19.5M+292.5%	$5.0M-92.5%	$65.9M+187.8%	$22.9M-63.2%	$62.1M
Investing Cash Flow	-$168.8M	-$179.5M-10.9%	-$161.9M+49.8%	-$322.4M-124.2%	-$143.8M-66.5%	-$86.3M+79.7%	-$425.4M-644.1%	-$57.2M+50.8%	-$116.1M-84.2%	-$63.0M+14.0%	-$73.3M+30.0%	-$104.8M+14.0%	-$121.8M-15.1%	-$105.8M+82.3%	-$596.4M-1042.6%	-$52.2M
Financing Cash Flow	-$227.5M	-$178.5M-264.0%	$108.8M+185.2%	$38.2M+138.0%	-$100.4M-537.3%	-$15.7M-104.3%	$367.5M+380.1%	-$131.2M-159.2%	-$50.6M+58.0%	-$120.6M-99.7%	-$60.4M+3.5%	-$62.6M-88.9%	-$33.2M-60.2%	-$20.7M-104.5%	$461.9M+1615.8%	-$30.5M
Share Buybacks	N/A	$175.0M-22.2%	$225.0M	$0-100.0%	$75.0M	$0	$0-100.0%	$175.0M+9.4%	$160.0M+60.0%	$100.0M	$0-100.0%	$61.0M+56.2%	$39.0M	$0-100.0%	$50.0M0.0%	$50.0M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$52.3M+200.8%	$70.9M-39.1%	$93.6M+113.8%	$111.3M+128.0%	$17.4M+163.4%	$116.6M+81.9%	$43.8M+8204.8%	$48.8M-50.7%
Depreciation & Amortization	$27.1M-5.7%	$27.3M-3.2%	$27.4M-5.7%	$28.3M-3.3%	$28.8M-1.3%	$28.2M+2.1%	$29.0M+23.5%	$29.2M+27.0%
Stock-Based Compensation	$9.3M0.0%	N/A	$7.8M-5.1%	$7.6M+10.7%	$9.3M+22.1%	N/A	$8.2M	$6.9M
Capital Expenditures	$7.9M+110.6%	$17.7M+12.9%	$6.3M-25.7%	$5.0M-46.8%	$3.8M-33.6%	$15.6M+134.0%	$8.5M-41.6%	$9.4M+3.5%
Free Cash Flow	$44.4M+225.6%	$53.3M-47.2%	$87.2M+147.6%	$106.3M+169.9%	$13.6M+141.2%	$100.9M+75.8%	$35.2M+331.9%	$39.4M-56.2%
Investing Cash Flow	-$22.2M+32.6%	-$86.6M-580.1%	-$29.5M-69.6%	-$30.5M-30.4%	-$33.0M+76.3%	$18.0M+238.2%	-$17.4M+93.5%	-$23.4M+7.0%
Financing Cash Flow	-$51.5M-2010.1%	-$101.5M+33.0%	$2.0M+47.3%	-$76.6M-2.3%	-$2.4M-100.7%	-$151.4M-138.5%	$1.4M-98.7%	-$74.8M-943.0%
Share Buybacks	N/A	$100.0M-33.3%	$0	N/A	N/A	$150.0M	$0	N/A

Not reported in any period shown, so not listed: Dividends Paid.

HAE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HAE quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	59.0%+4.0pp	55.0%+2.2pp	52.8%+0.2pp	52.6%+1.7pp	50.9%+5.2pp	45.7%-3.3pp	49.0%+5.9pp	43.1%-2.4pp	45.6%+2.9pp	42.7%-2.0pp	44.7%-3.1pp	47.7%-2.2pp	49.9%+1.9pp	48.0%-2.7pp	50.7%
Operating Margin	11.8%-4.6pp	16.3%+3.7pp	12.6%-0.8pp	13.4%+5.2pp	8.1%-2.2pp	10.3%-0.2pp	10.5%+1.8pp	8.6%+2.4pp	6.2%+8.4pp	-2.2%+2.6pp	-4.8%-9.3pp	4.5%-0.5pp	5.0%-1.4pp	6.3%-5.9pp	12.2%
Net Margin	0.0%0.0pp	0.0%-9.0pp	9.0%-0.9pp	9.9%+5.5pp	4.4%-4.8pp	9.1%+1.4pp	7.7%+2.0pp	5.7%+0.6pp	5.0%+8.0pp	-3.0%+3.2pp	-6.1%-8.0pp	1.9%-1.9pp	3.8%-0.6pp	4.3%-4.8pp	9.2%
Return on Equity	0.0%0.0pp	0.0%-12.2pp	12.3%-1.9pp	14.1%+8.3pp	5.8%-5.1pp	10.9%-2.2pp	13.0%+4.8pp	8.2%+2.2pp	6.1%+9.6pp	-3.5%+4.2pp	-7.7%-9.8pp	2.1%-2.1pp	4.2%-0.9pp	5.0%-4.1pp	9.1%
Return on Assets	0.0%0.0pp	0.0%-5.3pp	5.3%-0.6pp	6.0%+3.6pp	2.3%-2.0pp	4.4%-1.7pp	6.0%+1.7pp	4.3%+0.6pp	3.7%+5.8pp	-2.1%+2.1pp	-4.2%-5.3pp	1.1%-1.2pp	2.3%-0.3pp	2.6%-4.7pp	7.3%
Current Ratio	2.95+1.3x	1.62-0.9x	2.56-0.5x	3.06+1.3x	1.71-1.0x	2.74+0.5x	2.20-0.2x	2.44+1.1x	1.35-1.1x	2.42-0.2x	2.63-0.3x	2.96+0.1x	2.87-0.4x	3.31-0.7x	4.03
Debt-to-Equity	1.53+0.4x	1.12+0.3x	0.83-0.1x	0.92+0.2x	0.75-0.2x	0.94+0.4x	0.520.0x	0.48+0.4x	0.08-0.3x	0.34-0.2x	0.510.0x	0.490.0x	0.47-0.1x	0.59+0.6x	0.00
Asset Turnover	0.560.0x	0.560.0x	0.600.0x	0.60+0.1x	0.53+0.1x	0.48-0.3x	0.780.0x	0.760.0x	0.730.0x	0.720.0x	0.69+0.1x	0.610.0x	0.620.0x	0.61-0.2x	0.80
FCF Margin	19.5%+9.1pp	10.5%-0.5pp	11.0%+4.0pp	7.0%-0.6pp	7.6%-0.6pp	8.2%-2.8pp	11.1%+6.9pp	4.2%-11.9pp	16.1%+6.7pp	9.4%+7.3pp	2.1%+1.6pp	0.5%-6.5pp	7.0%+4.5pp	2.6%-6.0pp	8.5%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	59.8%-0.1pp	57.2%-1.2pp	59.7%+4.2pp	59.5%+5.2pp	59.8%+7.8pp	58.4%+7.2pp	55.5%+2.6pp	54.3%+0.7pp
Operating Margin	16.9%+0.2pp	-6.7%-28.2pp	19.9%+2.9pp	17.9%+2.9pp	16.8%+4.9pp	21.6%+12.9pp	16.9%+3.3pp	15.0%+3.9pp
Net Margin	9.7%-0.9pp	-33.9%-0.8pp	13.2%+2.4pp	11.8%+2.0pp	10.6%-0.8pp	-33.1%-39.1pp	10.8%+1.5pp	9.8%+2.0pp
Return on Equity	3.9%+0.1pp	-14.7%-1.4pp	4.9%+0.8pp	4.6%+0.7pp	3.9%-0.4pp	-13.3%-15.5pp	4.1%+0.8pp	3.9%+1.1pp
Return on Assets	1.4%0.0pp	-4.9%-0.4pp	1.8%+0.3pp	1.6%+0.2pp	1.4%-0.1pp	-4.5%-5.4pp	1.5%+0.1pp	1.3%+0.1pp
Current Ratio	3.08+1.4x	2.95+1.3x	1.75-2.2x	1.64-1.8x	1.72-2.0x	1.62-0.9x	3.97+1.0x	3.49+0.2x
Debt-to-Equity	1.40+0.4x	1.53+0.4x	1.01-0.3x	1.08-0.3x	1.04-0.3x	1.12+0.3x	1.34+0.4x	1.39+0.5x
Asset Turnover	0.140.0x	0.140.0x	0.140.0x	0.130.0x	0.130.0x	0.130.0x	0.140.0x	0.140.0x
FCF Margin	13.1%+8.8pp	15.4%-15.1pp	25.7%+15.6pp	32.5%+21.1pp	4.2%+14.1pp	30.5%+13.8pp	10.1%+14.6pp	11.4%-16.9pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Haemonetics Corp Mass HAE	FY2026	$1.3B	$97K	0.0%	$4.6B	58/100
Inspire Medical INSP	FY2025	$912.0M	$145.4M	16.0%	$1.8B	64/100
Alphatec Hldgs Inc ATEC	FY2025	$764.2M	-$143.4M	-18.8%	$1.4B	36/100
Integer Hldgs Corp ITGR	FY2025	$1.9B	$102.8M	5.5%	$4.3B	59/100
Livanova Plc LIVN	FY2025	$1.4B	-$242.5M	-17.5%	$4.4B	59/100
Procept Biorobotics Corp PRCT	FY2025	$308.1M	-$96K	0.0%	$1.2B	54/100

Where Haemonetics Corp Mass Ranks

Frequently Asked Questions

What is Haemonetics Corp Mass's annual revenue?

Haemonetics Corp Mass (HAE) reported $1.3B in total revenue for fiscal year 2026. This represents a -2.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Haemonetics Corp Mass's revenue growing?

Haemonetics Corp Mass (HAE) revenue declined by 2.0% year-over-year, from $1.4B to $1.3B in fiscal year 2026.

Is Haemonetics Corp Mass profitable?

Yes, Haemonetics Corp Mass (HAE) reported a net income of $97K in fiscal year 2026, with a net profit margin of 0.0%.

What is Haemonetics Corp Mass's EBITDA?

Haemonetics Corp Mass (HAE) had EBITDA of $268.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Haemonetics Corp Mass have?

As of fiscal year 2026, Haemonetics Corp Mass (HAE) had $245.4M in cash and equivalents against $1.2B in long-term debt.

What is Haemonetics Corp Mass's gross margin?

Haemonetics Corp Mass (HAE) had a gross margin of 59.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Haemonetics Corp Mass's operating margin?

Haemonetics Corp Mass (HAE) had an operating margin of 11.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Haemonetics Corp Mass's net profit margin?

Haemonetics Corp Mass (HAE) had a net profit margin of 0.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Haemonetics Corp Mass's return on equity (ROE)?

Haemonetics Corp Mass (HAE) has a return on equity of 0.0% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Haemonetics Corp Mass's free cash flow?

Haemonetics Corp Mass (HAE) generated $260.4M in free cash flow during fiscal year 2026. This represents a 82.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Haemonetics Corp Mass's operating cash flow?

Haemonetics Corp Mass (HAE) generated $293.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Haemonetics Corp Mass's total assets?

Haemonetics Corp Mass (HAE) had $2.4B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Haemonetics Corp Mass's capital expenditures?

Haemonetics Corp Mass (HAE) invested $32.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Haemonetics Corp Mass spend on research and development?

Haemonetics Corp Mass (HAE) invested $59.8M in research and development during fiscal year 2026.

Does Haemonetics Corp Mass buy back shares?

Yes, Haemonetics Corp Mass (HAE) spent $175.0M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Haemonetics Corp Mass have outstanding?

Haemonetics Corp Mass (HAE) had 45M shares outstanding as of fiscal year 2026.

What is Haemonetics Corp Mass's current ratio?

Haemonetics Corp Mass (HAE) had a current ratio of 2.95 as of fiscal year 2026, which is generally considered healthy.

What is Haemonetics Corp Mass's debt-to-equity ratio?

Haemonetics Corp Mass (HAE) had a debt-to-equity ratio of 1.53 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Haemonetics Corp Mass's return on assets (ROA)?

Haemonetics Corp Mass (HAE) had a return on assets of 0.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Haemonetics Corp Mass's P/E ratio?

Haemonetics Corp Mass (HAE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 27, 2026). The market capitalization is $4.6B as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Haemonetics Corp Mass's price-to-sales ratio?

Haemonetics Corp Mass (HAE) trades at 3.4x sales, its market capitalization divided by revenue of $1.4B revenue, trailing 12 months to June 27, 2026. The market capitalization is $4.6B as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Haemonetics Corp Mass's Altman Z-Score?

Haemonetics Corp Mass (HAE) has an Altman Z-Score of 2.94, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Haemonetics Corp Mass's Piotroski F-Score?

Haemonetics Corp Mass (HAE) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Haemonetics Corp Mass's earnings high quality?

Haemonetics Corp Mass (HAE) reported $97K of net income while generating $293.2M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Haemonetics Corp Mass cover its interest payments?

Haemonetics Corp Mass (HAE) has an interest coverage ratio of 8.12x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Haemonetics Corp Mass?

Haemonetics Corp Mass (HAE) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.